Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibiting the system xC-/glutathione axis selectively targets cancers with mutant-p53 accumulation.

Nature communications - 28 Mar 2017

Liu David S, Duong Cuong P, Haupt Sue, Montgomery Karen G, House Colin M, Azar Walid J, Pearson Helen B, Fisher Oliver M, Read Matthew, Guerra Glen R, Haupt Ygal, Cullinane Carleen, Wiman Klas G, Abrahmsen Lars, Phillips Wayne A, Clemons Nicholas J

Abstract excerpt

TP53, a critical tumour suppressor gene, is mutated in over half of all cancers resulting in mutant-p53 protein accumulation and poor patient survival. Therapeutic strategies to target mutant-p53 cancers are urgently needed. We show that accumulated mutant-p53 protein suppresses the expression of SLC7A11, a component of the cystine/glutamate antiporter, system xC-, through binding to the master antioxidant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to Glutathione

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lipid Peroxidation

Share to NF-E2-Related Factor 2

Share to Oxidative Stress

Share to Reactive Oxygen Species

Share to Stress, Physiological

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 28348409
DOI: 10.1038/ncomms14844
PMCID: PMC5379068

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibiting the system xC-/glutathione axis selectively targets cancers with mutant-p53 accumulation.PMID 28348409Read ↗

Tumor-Associated Antigen xCT and Mutant-p53 as Molecular Targets for New Combinatorial Antitumor Strategies.Semantic proximity Read ↗

Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapySemantic proximity Read ↗

Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma.Semantic proximity Read ↗

Patient-Specific Pharmacogenomics unveils xCT as a Key Regulator for Druggable Metabolic and Proliferation Pathways in Colon CancerSemantic proximity Read ↗

SLC7A11 Overexpression in Glioblastoma Is Associated with Increased Cancer Stem Cell-Like Properties.Semantic proximity Read ↗

SLC7A11 is a superior determinant of APR-246 (Eprenetapopt) response than <i>TP53</i> mutation statusSemantic proximity Read ↗

SLC7A11 Is a Superior Determinant of APR-246 (Eprenetapopt) Response than TP53 Mutation Status.Semantic proximity Read ↗

Targeting SLC3A2 Subunit of System XC- is Essential for m6A Reader YTHDC2 to be an Endogenous Ferroptosis Inducer in Lung AdenocarcinomaSemantic proximity Read ↗

NRF2 activation by cysteine as a survival mechanism for triple-negative breast cancer cellsSemantic proximity Read ↗

Regulation of SLC7A11 as an unconventional checkpoint in tumorigenesis through ferroptosisSemantic proximity Read ↗

Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancerSemantic proximity Read ↗

NRF2 activation by cysteine as a survival mechanism for triple-negative breast cancer cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.